Please provide your email address to receive an email when new articles are posted on . The FDA approved pemigatinib for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and ...
The Food and Drug administration has approved Pemazyre for patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement. The Food and Drug Administration (FDA) ...
The approval was based on data from the phase 2 FIGHT-203 study, which included 28 patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. The Food and Drug ...
Incyte today announced that the U.S. Food and Drug Administration has approved Pemazyre ®, a selective fibroblast growth factor receptor inhibitor, for the treatment of adults with relapsed or ...
(RTTNews) - Incyte Corp. (INCY) said that the U.S. Food and Drug Administration has approved Pemazyre (pemigatinib), a selective fibroblast growth factor receptor or FGFR inhibitor, for the treatment ...
Analysis of >40 subtypes of lymphoid blood cancer tracked by the UK Haematological Malignancy Research Network reveals wide incidence and survival variation, but distinct gains in survival since ...
The FDA Friday approved pemigatinib (Pemazyre), a selective fibroblast growth factor (FGFR) inhibitor, to treat adults who have relapsed or refractory (R/R) myeloid/lymphoid neoplasms (MLNs) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback